Piramal Pharma Dividends and Buybacks
Dividend criteria checks 0/6
Piramal Pharma is a dividend paying company with a current yield of 0.042%.
Key information
0.04%
Dividend yield
-3.0%
Buyback Yield
| Total Shareholder Yield | -2.9% |
| Future Dividend Yield | 0.4% |
| Dividend Growth | 110.4% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | ₹0.110 |
| Payout ratio | 79% |
Recent dividend and buyback updates
Recent updates
₹284 - That's What Analysts Think Piramal Pharma Limited (NSE:PPLPHARMA) Is Worth After These Results
Oct 26
Piramal Pharma (NSE:PPLPHARMA) Takes On Some Risk With Its Use Of Debt
Oct 25Here's Why Piramal Pharma (NSE:PPLPHARMA) Has A Meaningful Debt Burden
Jul 14Estimating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Jun 17We Think That There Are Issues Underlying Piramal Pharma's (NSE:PPLPHARMA) Earnings
May 21It's A Story Of Risk Vs Reward With Piramal Pharma Limited (NSE:PPLPHARMA)
Mar 26Estimating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Feb 28Earnings Update: Here's Why Analysts Just Lifted Their Piramal Pharma Limited (NSE:PPLPHARMA) Price Target To ₹161
Feb 02Calculating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Nov 09Calculating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Aug 11Stability and Growth of Payments
Fetching dividends data
Stable Dividend: PPLPHARMA is not paying a notable dividend for the Indian market, therefore no need to check if payments are stable.
Growing Dividend: PPLPHARMA is not paying a notable dividend for the Indian market, therefore no need to check if payments are increasing.
Dividend Yield vs Market
| Piramal Pharma Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (PPLPHARMA) | 0.04% |
| Market Bottom 25% (IN) | 0.2% |
| Market Top 25% (IN) | 1.1% |
| Industry Average (Pharmaceuticals) | 0.7% |
| Analyst forecast (PPLPHARMA) (up to 3 years) | 0.4% |
Notable Dividend: PPLPHARMA's dividend (0.042%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.24%).
High Dividend: PPLPHARMA's dividend (0.042%) is low compared to the top 25% of dividend payers in the Indian market (1.12%).
Earnings Payout to Shareholders
Earnings Coverage: PPLPHARMA is not paying a notable dividend for the Indian market.
Cash Payout to Shareholders
Cash Flow Coverage: PPLPHARMA is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 03:35 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Piramal Pharma Limited is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kunal Randeria | Axis Capital Limited |
| Prakash Agarwal | Axis Capital Limited |
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |